148,256 Shares in Medpace Holdings, Inc. $MEDP Acquired by Grandeur Peak Global Advisors LLC

Grandeur Peak Global Advisors LLC bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 148,256 shares of the company’s stock, valued at approximately $1,333,000.

A number of other hedge funds have also modified their holdings of the stock. Johnson Financial Group Inc. purchased a new stake in shares of Medpace in the second quarter valued at $27,000. Geneos Wealth Management Inc. grew its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Elyxium Wealth LLC purchased a new position in shares of Medpace during the fourth quarter valued at $30,000. Jones Financial Companies Lllp acquired a new position in Medpace during the second quarter valued at $30,000. Finally, Allied Private Wealth LLC purchased a new stake in Medpace in the 2nd quarter worth about $31,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Down 1.2%

Shares of MEDP stock opened at $611.57 on Friday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The business’s 50 day moving average is $562.52 and its two-hundred day moving average is $493.80. The company has a market cap of $17.07 billion, a PE ratio of 35.85, a price-to-earnings-growth ratio of 2.76 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the business earned $3.10 EPS. The business’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on MEDP. Mizuho raised their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Robert W. Baird increased their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. BMO Capital Markets lifted their target price on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $584.18.

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 27,174 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $618.79, for a total value of $16,814,999.46. Following the completion of the transaction, the chief executive officer directly owned 561,195 shares in the company, valued at approximately $347,261,854.05. This represents a 4.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the completion of the transaction, the vice president owned 62,984 shares of the company’s stock, valued at approximately $37,790,400. This represents a 10.64% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 129,963 shares of company stock valued at $79,364,624. 20.50% of the stock is currently owned by insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.